IQVIA (NYSE:IQV) vs. Adagio Medical (NASDAQ:ADGM) Head to Head Survey

IQVIA (NYSE:IQV) and Adagio Medical (NASDAQ:ADGM) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Profitability

This table compares IQVIA and Adagio Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IQVIA	8.07%	30.70%	6.64%
Adagio Medical	N/A	-791.01%	-199.58%

Earnings & Valuation

This table compares IQVIA and Adagio Medical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$15.90 billion	1.93	$1.37 billion	$7.29	24.78
Adagio Medical	$266,000.00	58.41	-$75.04 million	($1.52)	-0.66

IQVIA has higher revenue and earnings than Adagio Medical. Adagio Medical is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

89.6% of IQVIA shares are owned by institutional investors. Comparatively, 48.1% of Adagio Medical shares are owned by institutional investors. 1.6% of IQVIA shares are owned by company insiders. Comparatively, 5.2% of Adagio Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

IQVIA has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500. Comparatively, Adagio Medical has a beta of 0.13, suggesting that its share price is 87% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for IQVIA and Adagio Medical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	0	4	12	2	2.89
Adagio Medical	1	0	1	0	2.00

IQVIA presently has a consensus price target of $250.13, suggesting a potential upside of 38.48%. Adagio Medical has a consensus price target of $4.00, suggesting a potential upside of 296.04%. Given Adagio Medical’s higher possible upside, analysts plainly believe Adagio Medical is more favorable than IQVIA.

Summary

IQVIA beats Adagio Medical on 12 of the 15 factors compared between the two stocks.

About IQVIA

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients’ outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.

About Adagio Medical

Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company’s product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. The company is based in Laguna Hills, California.